A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

Blumenschein, G.R., Smit, E.F., Planchard, D., Kim, D.-W., Cadranel, J., De Pas, T., Dunphy, F., Udud, K., Ahn, M.-J., Hanna, N.H., Kim, J.-H., Mazieres, J., Kim, S.-W., Baas, P., Rappold, E., Redhu, S., Puski, A., Wu, F.S., Jänne, P.A.·2015·Annals of Oncology
DOI 10.1093/annonc/mdv072

Cited by (350)

Items 101–200 of 350

  1. KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
    Saveri Bhattacharya, Mark A. Socinski, Timothy Francis Burns · 2015 · Clinical and Translational Medicine
  2. KRAS: Reasons for optimism in lung cancer
    Colin R. Lindsay, Mariam Jamal‐Hanjani, Martin David Forster, Fiona Helen Blackhall · 2018 · European Journal of Cancer
  3. Cutaneous reactions in children treated with MEK inhibitors, BRAF inhibitors, or combination therapy: A multicenter study
    Christina L. Boull, Samantha Gardeen, Talal Abdali, Edward Li, Jolee G. Potts, Nathan Rubin, Valerie M. Carlberg, Deepti Gupta, Raegan D. Hunt, Minnelly Luu et al. · 2020 · Journal of the American Academy of Dermatology
  4. A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer
    David R. Gandara, Natasha B. Leighl, Jean‐Pierre Delord, Fabrice Barlési, Jaafar Bennouna, Gérard Zalcman, Jeffrey R. Infante, Karen L. Reckamp, Karen L. Kelly, Frances A. Shepherd et al. · 2016 · Journal of Thoracic Oncology
  5. Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions
    Katarzyna Szklener, Adam Michalski, Klaudia Żak, Michał Piwoński, Sławomir Mańdziuk · 2022 · Cells
  6. Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors
    Matthew Dankner, Yifan Wang, Rouhi Fazelzad, Benny Johnson, Caroline A. Nebhan, Ibiayi Dagogo‐Jack, Nathaniel James Myall, Georg Richtig, Jillian Wilhelmina Paulina Bracht, Marco Gerlinger et al. · 2022 · JCO Precision Oncology
  7. Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
    Alice Indini, Erika Rijavec, Michele Ghidini, Alessio Cortellini, Francesco Grossi · 2021 · Pharmaceutics
  8. New strategies in immunotherapy for non-small cell lung cancer.
    Daniel Ricardo Carrizosa, Kathryn Ann Gold · 2015 · PubMed Central
  9. Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC)
    Anna Spreafico, Amit M. Oza, Blaise Alexander Clarke, Helen J MacKay, Patricia H. Shaw, Marcus Otho Butler, Neesha C. Dhani, Stéphanie Lheureux, Michelle K. Wilson, Stephen A. Welch et al. · 2017 · Gynecologic Oncology
  10. MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
    Kiichiro Ninomiya, Kadoaki Ohashi, Go Makimoto, Shuta Tomida, Hisao Higo, Hiroe Kayatani, Takashi Ninomiya, Toshio Kubo, Eiki Ichihara, Katsuyuki Hotta et al. · 2018 · Scientific Reports
  11. Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy
    Jesse Boumelha, Míriam Molina‐Arcas, Julian Downward · 2023 · Clinical Cancer Research
  12. MEK inhibitors block growth of lung tumours with mutations in ataxia–telangiectasia mutated
    Smida, Michal, Fece de la Cruz, Ferran, Kerzendorfer, Claudia, Uras, Iris Z., Mair, Barbara, Mazouzi, Abdelghani, Suchankova, Tereza, Konopka, Tomasz, Katz, Amanda M., Paz, Keren et al. · 2016 · Nature Communications
  13. Overcoming KRAS-Mutant Lung Cancer
    Jia Luo, Jonathan M. L. Ostrem, Bruna Pellini, Denis Imbody, Yaakov E. Stern, Hitendra S. Solanki, Eric B. Haura, Liza C. Villaruz · 2022 · American Society of Clinical Oncology Educational Book
  14. More to the RAS Story: KRAS G12C Inhibition, Resistance Mechanisms, and Moving Beyond KRAS G12C
    Lietman, Caressa D., Johnson, Melissa L., McCormick, Frank, Lindsay, Colin R. · 2022 · American Society of Clinical Oncology Educational Book
  15. Treating KRAS -mutant NSCLC: latest evidence and clinical consequences
    Pilar Garrido, Maria Eugenia Olmedo, Ana Gómez, Luis Paz Ares, Fernando López‐Ríos, Juan Manuel Rosa-Rosa, José Palacios · 2017 · Therapeutic Advances in Medical Oncology
  16. KRAS inhibition in non–small cell lung cancer: Past failures, new findings and upcoming challenges
    Francesco Passiglia, Umberto Malapelle, Marzia Del Re, Luisella Righi, Fabio Pagni, Daniela Furlan, Romano Danesi, Giancarlo Troncone, Silvia Novello · 2020 · European Journal of Cancer
  17. RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients
    Umberto Malapelle, Francesco Passiglia, Chiara Cremolini, Maria Lucia Reale, Francesco Pepe, Pasquale Pisapia, Antonio Avallone, Diego Luigi Cortinovis, Alfonso De Stefano, Matteo Fassan et al. · 2021 · European Journal of Cancer
  18. A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations
    Sai Prasad Desikan, Farhad Ravandi, Naveen Pemmaraju, Marina Y Konopleva, Sanam Loghavi, Elias Joseph Jabbour, Naval Guastad Daver, Nitin Jain, Kelly Sharon Chien, Abhishek Maiti et al. · 2022 · Acta Haematologica
  19. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib
    Kang‐Seo Park, Bora Oh, Mi-Hee Lee, Ky‐Youb Nam, Hae Ran Jin, Hannah Yang, Junyoung Choi, Sang‐We Kim, Dae Ho Lee · 2015 · Cancer Letters
  20. Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics
    Shumei Kato, Jacob J. Adashek, Justin A. Shaya, Ryosuke Okamura, Rebecca E. Jimenez, Suzanna Lee, Jason Keith Sicklick, Razelle Kurzrock · 2021 · Clinical Cancer Research
  21. TRAIL receptors promote constitutive and inducible IL-8 secretion in non-small cell lung carcinoma
    Francesca Favaro, Fedra Luciano‐Mateo, Joaquim Moreno‐Càceres, Miguel Hernández-Madrigal, Demi Both, Chiara Montironi, Franziska Püschel, Ernest Nadal, Eric Eldering, Cristina Muñoz‐Pinedo · 2022 · Cell Death and Disease
  22. RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors
    Xi Yuan, Zhiyu Tang, Rong Du, Zhan Yao, Shing‐Hu Cheung, Xinwen Zhang, Jing Wei, Yuan Zhao, Yunguang Du, Ye Liu et al. · 2020 · Molecular Oncology
  23. New prospectives on treatment opportunities in RASopathies
    Bruce D. Gelb, Marielle E. Yohe, Cordula Maria Wolf, Grégor Andelfinger · 2022 · American Journal of Medical Genetics Part C Seminars in Medical Genetics
  24. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS
    Robert Jr. Roskoski · 2021 · Pharmacological Research
  25. Risk of Selected Cardiovascular Toxicities in Patients With Cancer Treated With MEK Inhibitors: A Comparative Systematic Review and Meta-Analysis
    Omar Mohammed Abdel-Rahman, Hesham M. Elhalawani, Hoda Ahmed · 2015 · Journal of Global Oncology
  26. Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I
    Archana Upadhya, Khushwant S. Yadav, Ambikanandan R. Misra · 2020 · Expert Opinion on Drug Delivery
  27. Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway
    Claudia Korzeniecki, Ronny Priefer · 2020 · European Journal of Medicinal Chemistry
  28. miR-16 regulates proliferation and invasion of lung cancer cells via the ERK/MAPK signaling pathway by targeted inhibition of MAPK kinase 1 (MEK1)
    TianMing Chen, Qi Xiao, Xiaojun Wang, Zhongqiu Wang, JingWen Hu, Zhi Zhang, Zhunan Gong, Shilin Chen · 2019 · Journal of International Medical Research
  29. Targeting RAS mutants in malignancies: successes, failures, and reasons for hope
    Hang Sheng Yang, Xinyi Zhou, Dongliang Fu, Chenqin Le, Jiafeng Wang, Quan Zhou, Xiangrui Liu, Ying Yuan, Kefeng Ding, Qian Xiao · 2022 · 癌症：英文版
  30. The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
    Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos, Lars D. Engstrom, Jade Laguer, Andrew Calinisan, Allan Hebbert, Laura M. Waters, Krystal Moya, Vickie Bowcut et al. · 2024 · Molecular Cancer Therapeutics
  31. ERK Inhibitor LY3214996-Based Treatment Strategies forRAS-Driven Lung Cancer
    Jens Köhler, Yutong Zhao, Jiaqi Li, Prafulla C. Gokhale, Hong L. Tiv, Aine Knott, Margaret K. Wilkens, Kara M. Soroko, Mika Lin, Chiara Ambrogio et al. · 2021 · Molecular Cancer Therapeutics
  32. Targeting KRAS in PDAC: A New Way to Cure It?
    Qianyu He, Zuojia Liu, Jin Wang · 2022 · Cancers
  33. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers
    Aaron N. Hata, Steve C. Rowley, Hannah L. Archibald, María Gomez‐Caraballo, F M Siddiqui, Fei Ji, Joonil Jung, Mark E. Light, J S Lee, Laurent Debüssche et al. · 2017 · Oncogene
  34. Screening of potential biomarkers and their predictive value in early stage non-small cell lung cancer: a bioinformatics analysis
    Hongbin Tu, Meihong Wu, Weiling Huang, Lixin Wang · 2019 · Translational Lung Cancer Research
  35. A Real-World Study in Advanced Non–Small Cell Lung Cancer with KRAS Mutations
    Lei Lei, Wenxian Wang, Zongyang Yu, Xianbin Liang, Weiwei Pan, Huafei Chen, Liping Wang, Yong Fang, Min Wang, C. Xu et al. · 2019 · Translational Oncology
  36. Targeting NRAS-Mutant Cancers with the Selective STK19 Kinase Inhibitor Chelidonine
    Ling Mei Qian, Kun Chen, Changhong Wang, Zhen Chen, Zhiqiang Meng, Peng Wang · 2020 · Clinical Cancer Research
  37. IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors
    Michael J. Allegrezza, Melanie R. Rutkowski, Tom Li Stephen, Nikolaos Svoronos, Amelia J. Tesone, Alfredo Perales‐Puchalt, Jenny M. Nguyen, Fahmida Sarmin, Mee Rie Sheen, Emily K. Jeng et al. · 2016 · Cancer Research
  38. Efficacy and Safety of Trametinib in Neurofibromatosis Type 1-Associated Plexiform Neurofibroma and Low-Grade Glioma: A Systematic Review and Meta-Analysis
    Dun Wang, Lingling Ge, Zizhen Guo, Yuehua Li, Beiyao Zhu, Wei Wang, Chengjiang Wei, Qingfeng Li, Zhichao Wang · 2022 · Pharmaceuticals
  39. KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions
    Nastaran Karimi, Seyed Javad Moghaddam · 2023 · Cells
  40. Discovery of a Potent and Oral Available Complex I OXPHOS Inhibitor That Abrogates Tumor Growth and Circumvents MEKi Resistance
    Peng He, Juanjuan Feng, Xinting Xia, Yue Sun, Jia He, Tian Guan, Yangrui Peng, Xueli Zhang, Mingyao Liu, Xiufeng Pang et al. · 2023 · Journal of Medicinal Chemistry
  41. Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review
    Fernand Bteich, Mahshid Mohammadi, T. Li, Muzaffer Ahmed Bhat, Amalia A. Sofianidi, Ning Wei, Chaoyuan Kuang · 2023 · International Journal of Molecular Sciences
  42. KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges
    Serena Ceddia, Lorenza Maria Landi, Federico Cappuzzo · 2022 · International Journal of Molecular Sciences
  43. Risk of peripheral edema in cancer patients treated with MEK inhibitors: a systematic review and meta-analysis of clinical trials
    Yong Yang, Yi-Hua Liu, Xu Sun, Mingwei Yu, Lin Yang, Peiyu Cheng, Guowang Yang, Xiaomin Wang · 2017 · Current Medical Research and Opinion
  44. Integrative single-cell analysis of LUAD: elucidating immune cell dynamics and prognostic modeling based on exhausted CD8+ T cells
    Han Zhang, Pengpeng Zhang, Xuefeng Lin, Lin Tan, Yuhang Wang, Xiaoteng Jia, Kai Wang, Xin Li, Daqiang Sun · 2024 · Frontiers in Immunology
  45. Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
    Marc Cucurull, Lucía Notario, Montse Sánchez‐Céspedes, Cinta Hierro, Anna Estival, Enric Carcereny, Maria Saigí · 2022 · Frontiers in Oncology
  46. The kinase PLK1 promotes the development of Kras / Tp53 -mutant lung adenocarcinoma through transcriptional activation of the receptor RET
    Yifan Kong, Derek B. Allison, Qiongsi Zhang, Daheng He, Yuntong Li, Fengyi Mao, Chaohao Li, Zhiguo Li, Yanquan Zhang, Jianlin Wang et al. · 2022 · Science Signaling
  47. Hypertension in cancer patients treated with anti-angiogenic based regimens
    Yishay Wasserstrum, Ran Kornowski, Pia Raanani, Avi Leader, Oren Pasvolsky, Zaza Iakobishvili · 2015 · Cardio-Oncology
  48. Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC
    Jessica Marie Konen, B. Leticia Rodriguez, Aparna Padhye, Joshua Kapere Ochieng, Laura Gibson, Lixia Diao, Natalie Wall Fowlkes, Jared J. Fradette, David H. Peng, Robert J. Cardnell et al. · 2021 · Cancer Research
  49. Inhibition of SHP2 as an approach to block RAS-driven cancers
    Yu‐Ting Chou, Trever Grant Bivona · 2022 · Advances in cancer research
  50. Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists
    Kim Tam Bui, Wendy A. Cooper, Steven Kao, Michael Joseph Boyer · 2018 · Journal of Clinical Medicine
  51. PTPN2 regulates the activation of KRAS and plays a critical role in proliferation and survival of KRAS-driven cancer cells
    Zhangsen Huang, Mingzhu Liu, Donghe Li, Yun Tan, Ruihong Zhang, Zhizhou Xia, Peihong Wang, Bo Jiao, Ping Liu, Ruibao Ren · 2020 · Journal of Biological Chemistry
  52. A Critical Review of the Prognostic and Predictive Implications of KRAS and STK11 Mutations and Co-Mutations in Metastatic Non-Small Lung Cancer
    Peter Manolakos, Linda D. Ward · 2023 · Journal of Personalized Medicine
  53. A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC
    Nicholas Dompe, Christiaan N. Klijn, Sara A. Watson, Katherine Welker Leng, Jenna M. Port, Trinna L. Cuellar, Colin K. Watanabe, Benjamin Haley, Richard M. Neve, Marie Evangelista et al. · 2018 · PLoS ONE
  54. SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC
    Yuan, Man, Xu, Lin-feng, Zhang, Juan, Kong, Si-yuan, Wu, Man, Lao, Yuan-zhi, Zhou, Hua, Zhang, Li, Xu, Hongxi · 2019 · Frontiers in Oncology
  55. PAGER 2.0: an update to the pathway, annotated-list and gene-signature electronic repository for Human Network Biology
    Yue, Zongliang, Zheng, Qi, Neylon, Michael T, Yoo, Minjae, Shin, Jimin, Zhao, Zhiying, Tan, Aik Choon, Chen, Jake Y · 2018 · Nucleic Acids Research
  56. Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non–Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure
    David Allen Barbie, Alexander I. Spira, Karen L. Kelly, Rita Humeniuk, Jun Kawashima, Shengchun Kong, Marianna Koczywas · 2018 · Clinical Lung Cancer
  57. Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts
    Joshua C. Rosen, Jessica Weiss, Nhu‐An Pham, Quan Li, Sebastião N. Martins-Filho, Yuhui Wang, Ming‐Sound Tsao, Nadeem Moghal · 2021 · Translational Oncology
  58. Cutaneous Reactions in Children Treated with the Mitogen‐Activated Protein Kinase Extracellular Signal‐Regulated Kinase Inhibitor Trametinib for Neural Tumors
    Christina L. Boull, Kristen P. Hook, Christopher L. Moertel, Sheilagh Maguiness · 2016 · Pediatric Dermatology
  59. Risk of Selected Dermatological Toxicities in Cancer Patients Treated with MEK Inhibitors: A Comparative Systematic Review and Meta-Analysis
    Omar Mohammed Abdel-Rahman, Hesham M. Elhalawani, Hoda Ahmed · 2015 · Future Oncology
  60. RASA1/NF1-Mutant Lung Cancer: Racing to the Clinic?
    Kitajima, Shunsuke, Barbie, David A. · 2018 · Clinical Cancer Research
  61. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas
    Laura Esteban-Burgos, Haiyun Wang, Patricia Nieto, Jie Zheng, Carmen Blanco‐Aparicio, Carmen Varela, Gonzalo Goméz-López, Fernando Fernández-García, Manuel Sanclemente, Carmen E. Guerra et al. · 2020 · Proceedings of the National Academy of Sciences
  62. Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma
    Natalia Garcia, Vanessa Del Pozo, Marielle E. Yohe, Craig M. Goodwin, Terry J. Shackleford, Long Wang, Kunal Baxi, Yidong Chen, Anna T. Rogojina, Sara M. Zimmerman et al. · 2021 · Molecular Cancer Therapeutics
  63. Targeting RAS in neuroblastoma: Is it possible?
    Lei Lin, Lei Miao, Huiran Lin, Jiwen Cheng, Meng Li, Zhenjian Zhuo, Jing He · 2021 · Pharmacology & Therapeutics
  64. My personal mutanome: a computational genomic medicine platform for searching network perturbing alleles linking genotype to phenotype
    Yadi Zhou, Junfei Zhao, Jiansong Fang, William Martin, Lang Li, Ruth Nussinov, Timothy An-thy Chan, Charis Eng, Feixiong Cheng · 2021 · Genome biology
  65. Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer
    Nardi, Francesca, Perurena, Naiara, Schade, Amy E., Li, Ze-Hua, Ngo, Kenneth, Ivanova, Elena V., Saldanha, Aisha, Li, Chendi, Gokhale, Prafulla C., Hata, Aaron N. et al. · 2023 · Journal of Clinical Investigation
  66. The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
    Saturno, G., Lopes, F., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Zambon, A., Davies, L., Johnson, L., Preece, N., Lee, R., Viros, A. et al. · 2021 · Annals of Oncology
  67. Metabolic Remodelling: An Accomplice for New Therapeutic Strategies to Fight Lung Cancer
    Mendes, Cindy, Serpa, Jacinta · 2019 · Antioxidants
  68. Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations
    Matthias Scheffler, Alessandra M. E. Holzem, Anna Kron, Lucia Nogová, Michaela A. Ihle, Cornelia von Levetzow, Jana Fassunke, Claudia Wompner, Elisabeth Bitter, Sophia Koleczko et al. · 2020 · Lung Cancer
  69. Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
    Shirish M. Gadgeel, Jieling Miao, Jonathan Wesley Riess, James Moon, Philip C. Mack, Gregory James Gerstner, Timothy Francis Burns, Asma Taj, Wallace Akerley, Konstantin H. Dragnev et al. · 2023 · Clinical Cancer Research
  70. Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
    Javier Torres-Jiménez, Javier Baena Espinar, Helena Bote, Maria Zurera Berjaga, Jorge Esteban-Villarrubia, Jon Zugazagoitia Fraile, Luis G Paz-Ares · 2024 · Drugs
  71. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation
    Ander Puyalto, María Rodríguez‐Remírez, Inés López, Irati Macaya, Elizabeth Guruceaga, María Olmedo, A. Vilalta, Connor Welch, Sergio Sandiego, Silvestre Vicent et al. · 2024 · Molecular Cancer
  72. Super enhancer associated RAI14 is a new potential biomarker in lung adenocarcinoma
    Chongze Yuan, Hong Hu, Muyu Kuang, Zongwei Chen, Xiaoting Tao, Shengjian Fang, Yihua Sun, Yawei Zhang, Haiquan Chen · 2017 · Oncotarget
  73. Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer
    Raghav Sundar, Maxime Chénard-Poirier, Dearbhaile Catherine Collins, Timothy A. Yap · 2017 · Frontiers in Medicine
  74. Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer
    Aparna Padhye, Jessica Marie Konen, B. Leticia Rodriguez, Jared J. Fradette, Joshua Kapere Ochieng, Lixia Diao, Jing Wang, Wei Lü, Luisa S. Solis, Harsh Batra et al. · 2021 · JCI Insight
  75. A Genomically and Clinically Annotated Patient-Derived Xenograft Resource for Preclinical Research in Non–Small Cell Lung Cancer
    Xing Yi Woo, Anuj Srivastava, Philip C. Mack, Joel H. Graber, Brian J. Sanderson, Michael W. Lloyd, Mandy Chen, Sergii Domanskyi, Regina F. Gandour‐Edwards, Rebekah A. Tsai et al. · 2022 · Cancer Research
  76. MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression
    Dylan Farnsworth, Yusuke Inoue, Fraser D. Johnson, Georgia de Rappard-Yuswack, Daniel Lu, Rocky Shi, Lok In Josephine Ma, Marissa S. Mattar, Romel Somwar, Marc Ladanyi et al. · 2022 · npj Precision Oncology
  77. Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver Mutations
    Paul C. Barnfield, Peter M. Ellis · 2016 · Drugs
  78. Survivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas
    Toshiyuki Sumi, Sachie Hirai, Miki Yamaguchi, Yusuke Tanaka, Makoto Tada, Gen Yamada, Tadashi Hasegawa, Yohei Miyagi, Toshiro Niki, Atsushi Watanabe et al. · 2018 · International Journal of Oncology
  79. A benzoxazole compound as a novel MEK inhibitor for the treatment of RAS/RAF mutant cancer
    Ying Cheng, Xingkai Wang, Xiangying Xia, Wei Yan Zhang, Hongqi Tian · 2019 · International Journal of Cancer
  80. Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma
    Anneleen Daemen, Jonathan E. Cooper, Szymon Myrta, Matthew J. Wongchenko, Eva Lin, Jason E. Long, Oded Foreman, Zora D. Modrusan, Jarrod R. Tremayne, Cecile C. de la Cruz et al. · 2020 · Clinical Cancer Research
  81. Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer
    Jennifer J. Lee, Vaibhav Jain, Ravi K. Amaravadi · 2021 · International Journal of Molecular Sciences
  82. Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2
    Kari Braun Wisinski, Yael Flamand, Melissa Ann Wilson, Jason J. Luke, Hussein A. Tawbi, Fangxin Hong, Edith Peterson Mitchell, James A. Zwiebel, Helen Chen, Robert J. Gray et al. · 2023 · JCO Precision Oncology
  83. Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context
    Alexander Le, Saeed K Alzghari, Gary W. Jean, Ninh My La-Beck · 2017 · Therapeutics and Clinical Risk Management
  84. Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer
    J. Nathaniel Diehl, Priya S. Hibshman, Irem Ozkan‐Dagliyan, Craig M. Goodwin, Sarah V. Howard, Adrienne D. Cox, Channing J. Der · 2022 · Advances in cancer research
  85. Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies
    Sajid Ullah Khan, Vivekananda Budamagunta, Daohong Zhou · 2023 · Advances in cancer research
  86. Inhibition of HSP90 sensitizes a novel Raf/ERK dual inhibitor CY-9d in triple-negative breast cancer cells
    Yujuan Chen, Xiaoyun Wang, Chuan Cao, Xiaodong Wang, Shufang Liang, Cheng Peng, Leilei Fu, Gu He · 2017 · Oncotarget
  87. Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation: A case report
    Miriam Champer, Devin Miller, Dennis Yi‐Shin Kuo · 2019 · Gynecologic Oncology Reports
  88. Targeted Therapies in Non-small-Cell Lung Cancer
    Addie Hill, Rohan V. Gupta, Dan Zhao, Ritika Vankina, Idoroenyi Usua Amanam, Ravi Salgia · 2019 · Cancer treatment and research
  89. RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: similarities and main differences for prognosis and therapies
    Giopanou, Ioanna, Pintzas, Alexandros · 2020 · Critical Reviews in Oncology/Hematology
  90. Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy
    Satoshi Matsusaka, Takashi Kobunai, Noriko Yamamoto, Keisho Chìn, Mariko Ogura, Gotaro Tanaka, Kazuaki Matsuoka, Yuichi Ishikawa, Nobuyuki Mizunuma, Toshiharu Yamaguchi · 2016 · Genes & Cancer
  91. Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report
    Pierre-Olivier Gaudreau, J. Jack Lee, John Victor Heymach, Don Lynn Gibbons · 2020 · Clinical Lung Cancer
  92. Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
    Elisa Baldelli, Emna El Gazzah, John Conor Moran, Kimberley Alex Hodge, Zarko Manojlovic, Rania Bassiouni, John David Carpten, Vienna Ludovini, Sara Baglivo, Lucio Crinò et al. · 2021 · Genes
  93. Targeting KRAS G12C mutation in lung adenocarcinoma
    Anjali Rohatgi, Ramaswamy Govindan · 2021 · Lung Cancer
  94. Fbxo45‐mediated NP‐STEP 46 degradation via K6 ‐linked ubiquitination sustains ERK activity in lung cancer
    Qian Wang, Ci Xu, Renjie Cai, Weishu An, Haihua Yuan, Ming Xu · 2022 · Molecular Oncology
  95. Targeting KRAS in NSCLC: Old Failures and New Options for “Non-G12c” Patients
    Francesca Jacobs, Massimiliano Cani, Umberto Malapelle, Silvia Novello, Valerio Maria Napoli, Paolo Bironzo · 2021 · Cancers
  96. Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations
    Omar Mohammed Abdel-Rahman · 2016 · Therapeutic Advances in Respiratory Disease
  97. Targeting Mutant KRAS for Anticancer Therapy
    Fengqian Chen, Martin Prince Alphonse, Yan Liu, Qi Liu · 2019 · Current Topics in Medicinal Chemistry
  98. KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies
    Nabih Naim, Sara Moukheiber, Samah Daou, Hampig Raphaël Kourié · 2021 · Critical Reviews in Oncology/Hematology
  99. Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis
    Omar Mohammed Abdel-Rahman, Hesham M. Elhalawani, Hoda Ahmed, Mahmoud Ellithy · 2015 · Expert Review of Gastroenterology & Hepatology
  100. Impact of trametinib on the neuropsychological profile of NF1 patients
    Ève Lalancette, Édith Cantin, Marie-Ève Routhier, Chantal Mailloux, Marie-Claude Bertrand, Dorsa Sadat Kiaei, Valérie Larouche, Uri Y. Tabori, Cynthia E Hawkins, Benjamin Ellezam et al. · 2024 · Journal of Neuro-Oncology